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Background: Statin therapy is well documented to lower cholesterol and prevent cardiovascular adverse events. However, 10-15% of patients 
cannot tolerate many statins due to the development of myalgias. Pitavastatin, a newer statin, is minimally affected by the cytochrome P450 system, 
water soluble so it doesn’t enter the brain, and does not lower Co-enzyme Q10. However, whether these special biochemical characteristics make 
pitavastatin both usable and efficacious among patients who have not been able to tolerate other statins is not known.
methods: A total of 40 consecutive patients with documented intolerance to any dose of at least two different statins were prospectively enrolled 
into a protocol whereby they received a trial of pitavastatin therapy at a dose of 2 mg per day. Initially pitavastatin samples were provided and if 
they could tolerate the regimen, a long-term prescription was given. Baseline clinical characteristics in all patients and fasting baseline and post-
pitavastatin treatment fasting LDL cholesterol levels were obtained in all patients found to tolerate pitavastatin therapy. 
results: A total of 40 patients (mean age = 65 years; males = 40%, documented CAD = 50%; hypertension = 80%, diabetes = 18%, positive family 
history of CAD = 58%, smoker = 10%) were enrolled in the protocol. Of these 27 (68%) were able to tolerate the pitavastatin samples and continued 
on maintenance pitavastatin therapy. Among those able to tolerate pitavastatin, baseline fasting LDL cholesterol was reduced from 147±27 mg/dL 
to 93±25 mg/dL, resulting in an average LDL-cholesterol reduction of 34%. Patients who could best tolerate pitavastatin tended to be males and 
those with no history of coronary artery disease or diabetes.
conclusion: Low dose pitavastatin is an acceptable alternative to abandoning statin therapy among two thirds of patients documented to be 
intolerant to other statins, providing an average LDL-cholesterol reduction of 34%.
